Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
225.71
+7.28 (3.33%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Biogen Revenue
Biogen had revenue of $2.74B in the quarter ending June 30, 2026, with 3.42% growth. This brings the company's revenue in the last twelve months to $10.03B, up 0.31% year-over-year. In the year 2025, Biogen had annual revenue of $9.89B with 2.22% growth. That makes Biogen the 1,458th largest company in the world by revenue and 448th in the United States.
Revenue (ttm)
$10.03B
Revenue Growth
+0.31%
P/S Ratio
3.33
Revenue / Employee
$1,337,053
Employees
7,500
Market Cap
33.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.89B | 214.70M | 2.22% |
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
| GSK plc | 44.05B |
| Amgen | 38.10B |
BIIB News
- 1 day ago - Biogen price target raised to $270 from $240 at UBS - TheFly
- 2 days ago - Biogen price target lowered to $256 from $260 at RBC Capital - TheFly
- 7 days ago - Biogen's experimental lupus drug shows benefit against skin symptoms - Reuters
- 7 days ago - Biogen says litifilimab demonstrates rapid, durable efficacy in Phase 2 data - TheFly
- 7 days ago - Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus - GlobeNewsWire
- 22 days ago - Biogen publishes results from adolescent subgroup of VALIANT study - TheFly
- 22 days ago - Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN - GlobeNewsWire
- 24 days ago - Eisai, Biogen announce Leqembi Pen has been approved in Japan - TheFly